INTRODUCTION
Acute lymphoblastic leukemia (ALL) accounts for less than 20% of adult acute leukemias. The t(4;11)(q21;q23) is a frequent abnormality in this disease [1] [2] [3] . This translocation fuses the ALL1 (MLL, HRX, Hrtx1) [4] [5] [6] [7] [8] gene to the AF4 gene. This alteration identifies a subset of ALL with aggressive clinical features and poor outcome 9, 10 . In addition, the ALL1(MLL)/AF4 fusion is associated with a pro-B immunophenotype 11 . This fusion gene is detectable in the vast majority of pro-B ALL cases in infancy 12 and only in 30-40% of adults 10 . Due to this association with age, in infancy the pro-B immunophenotype and t(4;11) have often been considered as equivalent prognostic factors.
By contrast, in adults the lack of the above mentioned strong association and the lack, until 1990, of a centralized diagnostic procedure in large cooperative studies, such as the GIMEMA 0288 trial 13 , may have underscored the adverse prognosis conferred by this genetic alterations.
Recently, among a series of adults with pro-B ALL receiving the conventional chemotherapy regimen of the GIMEMA 0496 trial, we demonstrated that the ALL1(MLL)/AF4 genotypic features was the only parameter conferring an adverse clinical outcome to this specific subset of ALL patients 10 . For these reasons, in the subsequent GIMEMA LAL 2000 study, the ALL1(MLL)/AF4
ALL positive patients would be managed more intensively with one course of HD Ara-C/Mitoxantrone and HSCT as consolidation treatments.
Therefore, herein, we report the clinical outcome of ALL1(MLL)/AF4 positive ALL patients entered into the two consecutive GIMEMA trials looking for possible differences between the two adopted strategies © F e r r a t a S t o r t i F o u n d a t i o n
DESIGN AND METHODS

Patients
Twenty-one adult (18 -60 years) patients with ALL1(MLL)/AF4 positive ALL were enrolled into the GIMEMA LAL 2000 study between January 2000 and September 2004, while 25 patients entered into the GIMEMA LAL 0496 study active between October 1996 and December 1999.
The diagnosis of ALL was based on standard morphologic and cytochemical evaluation 14 and on immunophenotypic criteria.
All patients gave informed consent for both treatment and diagnostic procedures. The two studies were approved by the our institutional review board.
Molecular analysis
Total RNA was extracted from cells cryopreserved in guanidium isothiocyanate according to the method of Chomczynsky and Sacchi 15 . The quality of RNA was assessed on an ethidium bromidestained 1% agarose gel containing 2.2 M formaldehyde.
In vitro reverse transcription of 1µg total RNA to cDNA was performed using the commercial kit 
Response criteria
All patients starting induction therapy have been considered for statistical analysis. Therapeutic responses was evaluated at the end of induction treatment in all cases. CR was defined as the normalization of peripheral blood count and less than 5% blasts in the bone marrow (BM) with normal cellularity. Relapse was defined as the reappearance of leukemic cells in the bone marrow (> 5% blasts) and/or reappearance of clinical evidence of the disease.
Statistical analysis
Differences in the distribution of factors in subgroups were analyzed by ! 2 or Fisher's exact test, and by the Kruskal-Wallis test, as appropriate. Overall Survival (OS) was defined as the time from diagnosis to death or date of the last follow-up; Disease Free Survival (DFS) was calculated from the time of achieving CR to relapse, death or date of last follow-up. The probabilities of OS and DFS were estimated using the Kaplan-Meier method; differences between distribution were evaluated by means of Log-Rank test; confidence intervals (C.I. 95%) were estimated using the Simon and Lee method. The hypothesis of proportionality was tested using Schoenfeld's partial residuals. All tests were 2-sided, accepting p !0.05 as indicating a statistically significant difference. All analyses where performed using the SAS software (SAS Institute, Cary, NC, USA).
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RESULTS AND DISCUSSION
In the present study we describe the clinical course of 46 ALL1(MLL)/AF4 positive adult ALL patients consecutively treated in two multicenter GIMEMA trials: this represents the largest cohort of patients showing this rare genetic alteration described in the literature. All patients had a pro-B ALL. As reported in Table 1 , the main clinic and biologic characteristics of the ALL1(MLL)/AF4
positive ALL patients did not differ between the two groups. The karyotype was available in 38 cases (83%) and a t(4;11)(q21;q23) cytogenetic alteration was detected in 31 cases. None of the cases showed a t(9;22) and/or expressed the BCR/ABL fusion. Thirteen patients received a transplant (5 autologous; 8 allogeneic) whereas 4 patients relapsed before transplant at a median time of 1.6 months (range 1.2-5.8) after CR; the remaining case was lost to follow-up. Since our analyses were based on the intention to treat, this latter patient was considered at risk for the time he persisted in follow-up, thereafter he was censored at the time he became lost to follow-up. Due to physician decision, two additional patients of the GIMEMA LAL 0496 study were allotransplanted in first CR. Therefore, altogether 15 patients were transplanted. Eight cases received HSC from a HLA identical donors, 1 from an unrelated and 1 from an aploidentical donor, whereas the remaining 5 cases received autologous HSC.
All transplanted patients received standard intensive conditioning regimens that in the majority of cases consisted of total body irradiation (TBI) and/or ciclophosphamide (CY) and busulphan and CY.
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The probabilities of OS and of DFS are reported in figure 1 . Although, we observed a trend toward significance when considering the differences in relapse rates between transplanted and not transplanted patients, the intensified strategy adopted in the LAL 2000 study, that included HSCT, did not favourably impact on the clinical outcome of ALL1(MLL)/AF4 positive ALL patients.
The present findings are not powered enough to answer the question on the efficacy of HSCT for the treatment of this rare leukemic subtype because patients receiving HSCT were too few to significantly impact on the DFS. However, it is worth noting that the lowest relapse rate was observed after allogeneic HSCT (3/10). Therefore, this latter should still be considered the treatment of choice for the treatment of this genetically characterized adult ALL subtype even if contrasting data have been reported. Results from the MRC/ECOG 2993 study 17 showed that, despite the use of HSCT in first CR, the t(4;11) alteration still identified patients with an adverse prognosis having low event free survival and OS rates, due in part to relapses but also to deaths in CR. By contrast, a superiority of allogeneic transplant was demonstrated by the results of the prospective multicenter LALA-94 study 18 which showed that allogeneic SCT was associated with a significantly improved DFS with a plateau at 18 months. The advantage of transplant procedures was also demonstrated by the German multicenter trials GMALL 04-89 19 in which, however, t(4;11) positive cases were included in the larger pro-B immunophenotypic subgroup, a leukemic subtype with a heterogeneous prognosis, as previously reported 10 .
When considering the efficacy of HSCT in hematological malignancies, it is necessary to consider several variables. One of the most important is the ability of pre-transplant treatments to eradicate the malignant clones to the maximum possible extent. This concept is based on several observations, and recently it has received further confirmation in Ph-positive ALL. The use of tyrosine kinase inhibitors before transplant, that results in an improved molecular remission rate, was associated with a significant improvement in disease outcome after transplantation. [20] [21] [22] Due to the limited number of our patients we cannot draw any definite conclusion. However, the failure of HSCT to improve results in our ALL1(MLL)/AF4 positive ALL patients might therefore be due to the weakness of the pre-transplant strategy rather than to the effect of HSCT It therefore appears that HSCT, to be effective, should be preceded by a more effective pretransplant treatment.
The risk of an early relapse in ALL1(MLL)/AF4 positive ALL patients should prompt the search for a potential donor as soon as a diagnosis is established.
In conclusion, ALL1(MLL)/AF4 positive ALL remains an attractive leukemic subtype to evaluate novel strategies in order to improve chemotherapy activity and/or reduce treatment toxicity.
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